Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
High FODMAP diet causes barrier loss via lipopolysaccharide-mediated mast cell activation
Prashant Singh, Gintautas Grabauskas, Shi-Yi Zhou, Jun Gao, Yawen Zhang, Chung Owyang
Prashant Singh, Gintautas Grabauskas, Shi-Yi Zhou, Jun Gao, Yawen Zhang, Chung Owyang
View: Text | PDF
Research Article Gastroenterology

High FODMAP diet causes barrier loss via lipopolysaccharide-mediated mast cell activation

  • Text
  • PDF
Abstract

Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) are carbohydrates thought to contribute to the symptoms of IBS. A diet in high in FODMAPs (HFM) induces gastrointestinal symptoms in patients with irritable bowel syndrome (IBS), and a diet low in FODMAPs (LFM) improves symptoms in up to 60% of patients with IBS. However, the mechanism by which FODMAPs affect IBS symptoms is unclear. We showed that mice fed on a HFM diet have mast cell activation and colonic barrier loss. Using mast cell–deficient mice with and without mast cell reconstitution, we showed that HFM-mediated colonic barrier loss is dependent on TLR4-dependent mast cell activation. In in vitro studies, we demonstrated that IBS fecal supernatant stimulates mast cells significantly more compared with fecal supernatant from healthy controls. This effect of IBS fecal supernatant on mast cell stimulation is ameliorated in the absence of the TLR4 receptor and after a LFM diet. We found that a LFM diet improves colonic barrier function and reduces mast cell activation while decreasing fecal LPS levels. Our findings indicate that a HFM diet causes mast cell activation via LPS, which in turn leads to colonic barrier loss, and a LFM diet reverses these pathophysiologic mucosal changes.

Authors

Prashant Singh, Gintautas Grabauskas, Shi-Yi Zhou, Jun Gao, Yawen Zhang, Chung Owyang

×

Figure 5

LFM diet improved barrier function and mast cell activation and reduced fecal LPS levels in patients with IBS-D.

Options: View larger image (or click on image) Download as PowerPoint
LFM diet improved barrier function and mast cell activation and reduced ...
Six patients with IBS-D were provided dietitian prepared LFM diet for 4 weeks, and all patients had a clinical response. Colonic biopsies and serum and fecal specimens were obtained from IBS-D before and after a 4-week LFM diet. (A) A LFM diet improved tight junction dysfunction seen in patients with IBS-D and significantly increased the gene expression of tight junction proteins ZO-1 and JAM-A. (B and C) This was accompanied with significant reduction in serum markers of mast cell activation (mast cell tryptase and histamine) and a decrease in fecal LPS levels (n = 6/group). (D) In a separate experiment, pre-LFM (baseline) and post-LFM (after 4-week LFM diet) IBS-D fecal supernatants (200 μL) from these patients (n = 5) were administered intracolonically every day for 5 days to naive mice. After 5-day intracolonic fecal supernatant administration, mice injected with post-LFM fecal supernatant had higher TEER and lower plasma FITC concentration compared with pre-LFM IBS fecal supernatant mice, suggesting that pre-LFM IBS fecal supernatant causes barrier loss, which is reversed by LFM. *P < 0.05, using paired t test (A–C) and unpaired t test (D).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts